参麦针剂协同腹腔化疗治疗进展期大肠癌的临床观察_临床医学论文.docVIP

参麦针剂协同腹腔化疗治疗进展期大肠癌的临床观察_临床医学论文 参麦针剂协同腹腔化疗治疗进展期大肠癌的临床观察_临床医学论文 作者：朱伟嵘，郑岚，郭元彪，袁建明，沈小珩 【关键词】 参麦针剂 ［摘要］ 目的：观察参麦针剂（Shenmai Injection, SMI）协同腹腔化疗（intraperitoneal chemotherapy, IPC）治疗进展期大肠癌根治术后患者的疗效。方法：进展期大肠癌根治术后行腹腔化疗患者58例，分成IPC组（22例）和SMI＋IPC组（36例）。IPC组行单纯腹腔化疗（5氟尿嘧啶联合顺铂）；SMI+IPC组采用参麦针剂协同腹腔化疗治疗。每4周为1个疗程，共4～6个疗程。近期疗效观察临床症状、生存质量，治疗前后血白细胞计数、肝肾功能、自然杀伤（natural killer, NK）细胞活性、T淋巴细胞亚群中T辅助与T抑制细胞比值（CD4/CD8）；远期疗效观察无瘤生存率。结果：SMI＋IPC组近期总有效率为83.33%，IPC组为63.64%，两组比较有统计学意义（P＜0.05)；SMI＋IPC能改善临床症状，提高生存质量，维持血白细胞的稳定，提高NK细胞活性和CD4/CD8的比值，与IPC组比较，均有统计学意义（P＜0.05或P＜0.01)。SMI＋IPC可提高患者5年无瘤生存率。结论：参麦针剂协同腹腔化疗是治疗进展期大肠癌根治术后患者的有效方法。 　　［关键词］ 参麦针剂; 腹腔化疗; 大肠癌; 临床研究 　　Clinical research of intraperitoneal chemotherapy plus Shenmai Injection in treating advanced colorectal cancer 　　ABSTRACT Objective: To study the effects of intraperitoneal chemotherapy (IPC) plus Shenmai Injection (SMI) in treating advanced colorectal cancer following radical resections. Methods: Fiftyeight cases of colorectal cancer in stage B2 and C following radical resections were divided into two groups: SMI＋IPC group (36 cases) and IPC group (22 cases). In the SMI＋IPC group, IPC (5fluorouracil combined with cisplatin) plus SMI was administered, while in the IPC group, only IPC was administered. Clinical symptoms, quality of life (Karnofsky score), white blood cell counts, natural killer cells and CD4/CD8 were observed, and diseasefree survival (DFS) rate was also evaluated. Results: The total shortterm response rate was 83.33% in the SMI＋IPC group, significantly higher than 63.64% in the IPC group (0.05). The data of clinical symptoms, quality of life, white blood cell counts, natural killer cells and CD4/CD8 in the SMI＋IPC group were also significantly improved as compared with those in the IPC group (P＜0.05 or P＜0.01). In the SMI＋IPC group, 1, 3 and 5year DFS rates were 91.7% (33/36), 77.8% (28/36) and 72.2% (26/36) respectively, and those in the IPC group were 90.9% (20/22), 72.7% (16/22) and 45.5% (10/22) respectively. The 5year DFS